Eisai, Inc. is a biopharmaceutical company focused on R&D for the treatment of cancer and infectious diseases. This project created a new pilot manufacturing plant to support early stage clinical trials. It involved demolition of three existing buildings and construction of a new facility. Aspects of the project included:
- 60,000 SF cGMP pilot plant to support manufacturing of advanced therapeutics.
- Integrated architecture and engineering that yielded a facility that marries form and function.
- Unidirectional circulation and viewing corridor that maximized building area dedicated to production.
- Mechanical catwalk that rings the production core and provided access to all building systems for ventilation and maintenance.
- Dual fixed and disposable technology that offered flexibility in manufacturing.
- Natural light that permeated most of the building, including office and laboratory areas.
- A plant that is 30% more water efficient, 33.2% more energy efficient, and offers a 90% more efficient HVAC system compared to a standard pharmaceutical facility.
- 85.2% efficiency with full systems redundancy that enabled complete segregation of production spaces in the event of a failure or contamination.
- A rooftop solar array that included 330 photovoltaic panels generating enough annual electricity to power six US houses for one year.
- The project was completed $3 million under budget in 18 months.
- BIM software enabled advanced coordination, team communication, and project organization.
Sustainable design and operational features of the project resulted in LEED Gold Certification. The project was the winner of the 2013 ISPE Facility of the Year Sustainability Category.
